Journal Mobile Options
Table of Contents
Vol. 9, No. 5, 2009
Issue release date: November 2009
Pancreatology 2009;9:621–630

Multidetector CT Evaluation of the Course of Nonresectable Pancreatic Carcinomas with Neoadjuvant Therapy

Klauss M. · Alt C.D. · Welzel T. · Werner J. · Büchler M.W. · Richter G.M. · Kauffmann G.W. · Kauczor H.U. · Grenacher L.
aDepartment of Diagnostic Radiology, bSurgical Clinic, and cDepartment of Therapeutic Radiology, University of Heidelberg, Heidelberg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: A prospective study to determine the value of multidetector CT (MD-CT) in assessing the course of nonresectable pancreatic carcinoma during therapy. Material and Methods: 26 patients with nonresectable pancreatic carcinoma underwent MD-CT before and after therapy. The examinations were evaluated with regard to tumor size and vascular invasion using an invasion score (IS) by 2 radiologists independently (κ analysis). Diagnosis was confirmed surgically, by biopsy or clinical course. Results: Sensitivity for the assessment of irresectability was 100%. Following therapy, 54% of all the tumors were smaller (14/26), 42% had increased in volume (11/26), and one tumor remained stable (1/26). The IS (veins) during follow-up changed in 26 patients (portal vein: 5 higher (mean score 10.4/16.2), 4 lower (mean score 17.5/11.5); superior mesenteric vein: 12 higher (11/14.4), 5 lower (16.2/14.6); p = 0.026). The IS (arteries) changed in 13 patients (celiac trunk: 3 higher (3.3/10); hepatic artery: 4 higher (5.7/10.2), 3 lower (11.6/10.3); superior mesenteric artery: 2 higher (4.5/9.5), 1 lower (12/11)). The κ values were calculated between 0.56 and 0.87. Conclusion: MD-CT is suitable for evaluating tumor spread during therapy for nonresectable pancreatic carcinoma. The IS is useful for assessing the degree of change in vessel invasion.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.
  2. Kleeff J, Michalski C, Friess H, Buchler MW: Pancreatic cancer: from bench to 5-year survival. Pancreas 2006;33:111–118.
  3. Kim R, Saif MW: Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? JOP 2007;8:279–288.

    External Resources

  4. Bold RJ, Charnsangavej C, Cleary KR, et al: Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999;3:233–243.
  5. Kleeff J, Friess H, Buchler MW: Neoadjuvant therapy for pancreatic cancer. Br J Surg 2007;94:261–262.
  6. NCCN: NCCN guidelines for treatment of pancreatic cancer 2006. In:, 2006.
  7. Chao C, Hoffman JP, Ross EA, Torosian MH, Eisenberg BL: Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience. Am Surg 2000;66:378–385, discussion 386.
  8. Beger HG, Poch B, Schwarz M, Gansauge F: Pancreatic cancer: the relative importance of neoadjuvant therapy. Chirurg 2003;74:202–207.
  9. Seufferlein T, von Wichert G, Adler G: Palliative treatment of pancreatic cancer. Dtsch Med Wochenschr 2007;132:813–817.
  10. Schima W, Ba-Ssalamah A, Kolblinger C, Kulinna-Cosentini C, Puespoek A, Gotzinger P: Pancreatic adenocarcinoma. Eur Radiol 2007;17:638–649.
  11. Schima W, Ba-Ssalamah A, Plank C, et al: Pancreas. II. Tumors. Radiologe 2006;46:421–437.
  12. Catalano C, Laghi A, Fraioli F, et al: Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability. Eur Radiol 2003;13:149–156.
  13. Brugel M, Link TM, Rummeny EJ, Lange P, Theisen J, Dobritz M: Assessment of vascular invasion in pancreatic head cancer with multislice spiral CT: value of multiplanar reconstructions. Eur Radiol 2004;14:1188–1195.
  14. Klauss M, Mohr A, von Tengg-Kobligk H, Friess H, Singer R, Seidensticker P, Kauczor HU, Richter GM, Kauffmann GW, Grenacher L: A new invasion score for determining the resectability of pancreatic carcinomas with contrast-enhanced multidetector computed tomography. Pancreatology 2008;8:204–210.
  15. Richter GM, Simon C, Hoffmann V, et al: Hydrospiral CT of the pancreas in thin section technique. Radiologe 1996;36:397–405.
  16. Richter GM, Wunsch C, Schneider B, et al: Hydro-CT in detection and staging of pancreatic carcinoma. Radiologe 1998;38:279–286.
  17. Li H, Zeng MS, Zhou KR, Jin DY, Lou WH: Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr 2005;29:170–175.
  18. Kundel HL, Polansky M: Measurement of observer agreement. Radiology 2003;228:303–308.
  19. Bland JM, Altman DG: Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135–160.
  20. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.
  21. Tamm EP, Loyer EM, Faria S, et al: Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy. Abdom Imaging 2006;31:568–574.
  22. Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB Jr: MDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. AJR Am J Roentgenol 2004;182:419–425.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50